Skip to main content
padlock icon - secure page this page is secure

Open Access Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study

Download Article:
 Download
(HTML 42.4 kb)
 
or
 Download
(PDF 92.6 kb)
 
Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a total of 20 patients with metastatic NSCLC adenocarcinoma with apatinib in combination with either pemetrexed or docetaxel from January 2016 to March 2017. The performance status of these patients was 0 or 1. All of these patients had been previously treated with two or more lines of treatment and had experienced disease progression prior to study enrollment. The overall objective response rate (ORR) was 30%, with 6 patients who had partial response (PR), 10 patients who had stable disease (SD), and 4 patients who had progressive disease (PD). The main adverse events were skin rash, hypertension, palmar‐plantar erythrodysesthesia syndrome, diarrhea, and fatigue. Nearly 30% of patients required interruption of treatment as a result of toxicity. Our study demonstrated that apatinib combined with systemic cytotoxic chemotherapy has clinical efficacy in patients with disease-refractory metastatic NSCLC and provides evidence for further studies investigating apatinib-based combination regimens.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Adenocarcinoma; Antiangiogenesis therapy; Apatinib; Cytotoxic chemotherapy; Non-small cell lung cancer (NSCLC)

Document Type: Research Article

Affiliations: 1: Department of Lymphoma in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China 2: Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, P.R. China 3: Department of People’s Hospital of Yicheng, Xiang yang City, Hubei Province, P.R. China 4: Centre of Molecular Diagnosis in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China 5: Department of 1st Division of Thoracic Tumor in Hubei Cancer Hospital, Wuhan City, Hubei Province, P.R. China

Publication date: June 21, 2019

This article was made available online on June 21, 2018 as a Fast Track article with title: "Apatinib plus chemotherapy shows clinical activity in advanced NSCLC: a retrospective study.".

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more